Figure 1: Immune cell depletion following alemtuzumab treatment in a human CD52-transgenic mouse model.
Absolute numbers of immune cell populations remaining at 72 hours after the administration of various intravenous doses of alemtuzumab were assessed. Results shown are the mean ± SEM of individual mice (n=5) and are expressed as the percentage of cells remaining after treatment relative to the number of cells present in vehicle-treated control mice (% Control). The organs examined included the blood (A), spleen (B), inguinal lymph nodes (C), and thymus (D). The cell populations analyzed consisted of CD4+ T cells, CD8+ T cells, single-positive (SP) and double-positive (DP) thymocytes, B220+ B cells, NK1.1+ CD49b+ NK cells and Gr-1+ neutrophils. (Reprinted from Figure 4 in Hu et al. [22].)